Literature DB >> 32048456

Precise anatomical resection based on structures of nerve and fibrous tissue around the superior mesenteric artery for mesopancreas dissection in pancreaticoduodenectomy for pancreatic cancer.

Yuichi Nagakawa1, Shuang-Qin Yi2, Chie Takishita1, Yatsuka Sahara1, Hiroaki Osakabe1, Yoshitaka Kiya1, Hiroshi Yamaguchi3, Yoko Miwa4, Iwao Sato4, Akihiko Tsuchida1.   

Abstract

BACKGROUND: The aim of the present study was to investigate the feasibility of resection based on the nerve and fibrous tissue (NFT) structures around the superior mesenteric artery (SMA) for resectable pancreatic adenocarcinoma (R-PDAC) patients.
METHODS: NFTs around the SMA were classified into four "intensive NTFs area" with spreading the NFTs around the SMA and three SMA nerve plexus regions without branching nerves according to autopsy findings. Complete dissection of four "intensive NTFs areas" was performed by pre-exposing three SMA nerve plexus regions without branching nerves as "dissection-guiding points" with SMA nerve plexus preservation (NFT-based resection). Among 157 R-PDAC patients undergoing pancreaticoduodenectomy, surgical outcomes of 78 patients with NFT-based resection were compared with 59 patients with half-SMA nerve plexus dissection and 20 patients without NFTs dissection.
RESULTS: In the NFT-based resection group, 76.5% had tumor involvement and metastasis in each intensive NTFs area. Operative time, blood loss, and postoperative diarrhea rate were significantly lower in NFT-based resection than in half-SMA nerve plexus group (321 vs 390 min; P < .01, 228 vs 550 mL; P < .01, 5.1% vs 15.3%; P = .04, respectively). R0 rate and median overall survival significantly improved in NFT-based resection than in non-NFT dissection group (93.6% vs 65.0%; P < .01, 49.6 vs 23.6 months, P = .01).
CONCLUSION: NFT-based resection may become a novel method for R-PDAC patients.
© 2020 Japanese Society of Hepato-Biliary-Pancreatic Surgery.

Entities:  

Keywords:  mesopancreas; nerve and fibrous tissue; pancreatic cancer; pancreaticoduodenectomy; superior mesenteric artery

Mesh:

Year:  2020        PMID: 32048456     DOI: 10.1002/jhbp.725

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Sci        ISSN: 1868-6974            Impact factor:   7.027


  9 in total

1.  Mesopancreas-new unknown land or a mirage?

Authors:  Marek Olakowski
Journal:  Langenbecks Arch Surg       Date:  2021-10-31       Impact factor: 3.445

2.  Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled Trial.

Authors:  Colin S Hill; Lauren Rosati; Hao Wang; Hua-Ling Tsai; Jin He; Amy Hacker-Prietz; Daniel A Laheru; Lei Zheng; Shuchi Sehgal; Vincent Bernard; Dung T Le; Timothy M Pawlik; Matthew J Weiss; Amol K Narang; Joseph M Herman
Journal:  Pract Radiat Oncol       Date:  2022-03-17

3.  Hydrogels for localized chemotherapy of liver cancer: a possible strategy for improved and safe liver cancer treatment.

Authors:  Jianyong Ma; Bingzhu Wang; Haibin Shao; Songou Zhang; Xiaozhen Chen; Feize Li; Wenqing Liang
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

Review 4.  What do surgeons need to know about the mesopancreas.

Authors:  Eduardo de Souza M Fernandes; Oliver Strobel; Camila Girão; Jose Maria A Moraes-Junior; Orlando Jorge M Torres
Journal:  Langenbecks Arch Surg       Date:  2021-06-12       Impact factor: 3.445

5.  Technical details of a left-side approach to the superior mesenteric artery during pancreaticoduodenectomy.

Authors:  Katsunori Sakamoto; Kohei Ogawa; Akihiro Takai; Kei Tamura; Mikiya Shine; Takashi Matsui; Yusuke Nishi; Takeshi Utsunomiya; Hitoshi Inoue; Seiji Matsuda; Yasutsugu Takada
Journal:  Surg Today       Date:  2021-02-27       Impact factor: 2.549

6.  Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity.

Authors:  Colin S Hill; Lauren M Rosati; Chen Hu; Wei Fu; Shuchi Sehgal; Amy Hacker-Prietz; Christopher L Wolfgang; Matthew J Weiss; Richard A Burkhart; Ralph H Hruban; Ana De Jesus-Acosta; Dung T Le; Lei Zheng; Daniel A Laheru; Jin He; Amol K Narang; Joseph M Herman
Journal:  Ann Surg Oncol       Date:  2022-02-07       Impact factor: 5.344

7.  High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients treated with stereotactic body radiation therapy following multi-agent chemotherapy.

Authors:  Colin Hill; Shuchi Sehgal; Wei Fu; Chen Hu; Abhinav Reddy; Elizabeth Thompson; Amy Hacker-Prietz; Dung Le; Ana De Jesus-Acosta; Valerie Lee; Lei Zheng; Daniel A Laheru; William Burns; Matthew Weiss; Christopher Wolfgang; Jin He; Joseph M Herman; Jeffrey Meyer; Amol Narang
Journal:  Cancer Med       Date:  2022-02-10       Impact factor: 4.452

Review 8.  Integrin β1 in Pancreatic Cancer: Expressions, Functions, and Clinical Implications.

Authors:  Jiajia Li; Liyao Peng; Qun Chen; Ziping Ye; Tiantian Zhao; Sicong Hou; Jianguo Gu; Qinglei Hang
Journal:  Cancers (Basel)       Date:  2022-07-11       Impact factor: 6.575

9.  Reconstructing topography and extent of injury to the superior mesenteric artery plexus in right colectomy with extended D3 mesenterectomy: a composite multimodal 3-dimensional analysis.

Authors:  Javier A Luzon; Yngve Thorsen; Liebert P Nogueira; Solveig N Andersen; Bjørn Edwin; Håvard J Haugen; Dejan Ignjatovic; Bojan V Stimec
Journal:  Surg Endosc       Date:  2022-04-05       Impact factor: 3.453

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.